Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche requests re-examination of Tarceva data
The European Committee for Medicinal Products for Human Use (CHMP) has responded unenthusiastically, despite Tarceva being the first treatment for many years to have shown significant survival benefits
The European Committee for Medicinal Products for Human Use (CHMP) has responded unenthusiastically, despite Tarceva being the first treatment for many years to have shown significant survival benefits
The trial will evaluate the safety, tolerability and pharmacokinetics of the oral treatment in 30 healthy adult male and female volunteers at one center. The drug is a
The two previously known types of sleep apnea are obstructive sleep apnea and central sleep apnea. In obstructive sleep apnea, the more common form, the throat muscles relax
The drugs, known as CDK inhibitors, can destroy the inflammatory cells that cause the tissue damage and scarring that leads to organ failure and joint pain. These drugs
These findings, which appear in The FASEB Journal, gave some indications as to which compounds may be responsible for causing key brain cells called neurons to regenerate and
The George Institute argues that drugs for neglected diseases are increasingly being developed partly due to the use of public-private partnership (PPP) mechanisms that spread the financial and
This first pooled analysis from phase II/III studies was presented by Novartis at the World Congress of Cardiology in Barcelona, Spain. Pooled data were available from over 7,000
Plasmodium falciparium is particularly dangerous for pregnant women, as it infects the placenta and is usually fatal for the mother and the fetus. This, combined with the often
The trial will start in mid-2007 and will be managed by The Henry M Jackson Foundation for the Advancement of Military Medicine in consultation with the clinical investigators
New analyses from the landmark PROactive study examined the effects of Actos on the risk of stroke and other cardiovascular outcomes in high-risk patients with type 2 diabetes,